In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ESP Pharma Inc.

Division of PDL BioPharma Inc.

Latest From ESP Pharma Inc.

Deal Update: Taking Stock of Biogen Idec

Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.

BioPharmaceutical Business Strategies

Early-Stage Biopharma Investors Opt for Safer Bets in 2002

Discovery risk is for VCs like yesterday's newspaper. With the Big Pharma market for discovery tools abysmally quiet, early-stage funding for such firms saw a steep decline.

BioPharmaceutical Strategy

Start-Up Previews (12/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Specialty Pharmaceuticals, features profiles of Advancis Pharmaceutical Corp., Avera Pharmaceuticals Inc., ESP Pharma Inc. and Ovation Pharmaceuticals Inc. Plus these Start-Ups across Health Care: Advanced Bio Prosthetic Surfaces Ltd., Aton Pharma Inc., Kerberos Proximal Solutions Inc. and Xeotron Corp.

Specialty Pharmaceuticals: Solving the Encore Problem

Even the most successful specialty pharmas hit a point where an in-licensing candidate has to be almost too costly in order to sustain the growth of the organization. Start-ups are trying to avoid this trap by developing capabilities that add significant value to an in-licensing candidate, or by having at the outset some approach to identifying products and niches that no one else can.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PDL BioPharma Inc.
  • Senior Management
  • John T Spitznagel, Chmn. & CEO
    Andrew J Einhorn, EVP, CFO
    Gregory J Stokes, VP, Corp. Dev.
    Howard J Weisman, Pres. & COO
  • Contact Info
  • ESP Pharma Inc.
    Phone: (732) 650-1377
    2035 Lincoln Hwy.
    Ste. 2150
    Edison, NJ 08817